<!doctype html><!-- This site was created with Wowchemy. https://www.wowchemy.com --><!-- Last Published: January 29, 2023 --><html lang=en-us><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Wowchemy 5.7.0 for Hugo"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=preload as=style href="https://fonts.googleapis.com/css2?family=B612+Mono&family=B612:wght@400;700&family=Jura:wght@400;700&display=swap"><link rel=stylesheet href="https://fonts.googleapis.com/css2?family=B612+Mono&family=B612:wght@400;700&family=Jura:wght@400;700&display=swap" media=print onload='this.media="all"'><link rel=stylesheet href=/css/vendor-bundle.min.16f785cdb553c8c4431db6775122af35.css media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/academicons@1.9.2/css/academicons.min.css integrity="sha512-KlJCpRsLf+KKu2VQa5vmRuClRFjxc5lXO03ixZt82HZUk41+1I0bD8KBSA0fY290ayMfWYI9udIqeOWSu1/uZg==" crossorigin=anonymous media=print onload='this.media="all"'><link rel=stylesheet href=/css/wowchemy.af55899d8b924748b901d470aa7b0bd6.css><link rel=stylesheet href=/css/libs/chroma/github-light.min.css title=hl-light media=print onload='this.media="all"'><link rel=stylesheet href=/css/libs/chroma/dracula.min.css title=hl-dark media=print onload='this.media="all"' disabled><meta name=author content="Mars (Shih-Cheng) Huang"><meta name=description content="In this study, we demonstrate prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies. We train and validate models using five phase III randomized trials conducted across hundreds of clinical centers. Compared to the most common risk-stratification tool—risk groups developed by the National Cancer Center Network (NCCN)—our models have superior discriminatory performance across all endpoints, ranging from 9.2% to 14.6% relative improvement in a held-out validation set."><link rel=alternate hreflang=en-us href=https://marshuang80.github.io/publication/prostate_multimodal/><link rel=canonical href=https://marshuang80.github.io/publication/prostate_multimodal/><link rel=manifest href=/manifest.webmanifest><link rel=icon type=image/png href=/media/icon_hu687e722fa5af903774003502d32d2ddb_42108_32x32_fill_lanczos_center_3.png><link rel=apple-touch-icon type=image/png href=/media/icon_hu687e722fa5af903774003502d32d2ddb_42108_180x180_fill_lanczos_center_3.png><meta name=theme-color content="#1565c0"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:site" content="@wowchemy"><meta property="twitter:creator" content="@wowchemy"><meta property="twitter:image" content="https://marshuang80.github.io/publication/prostate_multimodal/featured.jpeg"><meta property="og:site_name" content="Mars Huang"><meta property="og:url" content="https://marshuang80.github.io/publication/prostate_multimodal/"><meta property="og:title" content="Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials | Mars Huang"><meta property="og:description" content="In this study, we demonstrate prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies. We train and validate models using five phase III randomized trials conducted across hundreds of clinical centers. Compared to the most common risk-stratification tool—risk groups developed by the National Cancer Center Network (NCCN)—our models have superior discriminatory performance across all endpoints, ranging from 9.2% to 14.6% relative improvement in a held-out validation set."><meta property="og:image" content="https://marshuang80.github.io/publication/prostate_multimodal/featured.jpeg"><meta property="og:locale" content="en-us"><meta property="article:published_time" content="2022-04-20T00:00:00+00:00"><meta property="article:modified_time" content="2022-04-20T00:00:00+00:00"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://marshuang80.github.io/publication/prostate_multimodal/"},"headline":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","image":["https://marshuang80.github.io/publication/prostate_multimodal/featured.jpeg"],"datePublished":"2022-04-20T00:00:00Z","dateModified":"2022-04-20T00:00:00Z","author":{"@type":"Person","name":"Andre Esteva"},"publisher":{"@type":"Organization","name":"Mars Huang","logo":{"@type":"ImageObject","url":"https://marshuang80.github.io/media/icon_hu687e722fa5af903774003502d32d2ddb_42108_192x192_fill_lanczos_center_3.png"}},"description":"In this study, we demonstrate prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies. We train and validate models using five phase III randomized trials conducted across hundreds of clinical centers. Compared to the most common risk-stratification tool—risk groups developed by the National Cancer Center Network (NCCN)—our models have superior discriminatory performance across all endpoints, ranging from 9.2% to 14.6% relative improvement in a held-out validation set."}</script><title>Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials | Mars Huang</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents class=page-wrapper data-wc-page-id=6c4b09ad8cf5500f99aba4278572177b><script src=/js/wowchemy-init.min.ec9d49ca50e4b80bdb08f0417a28ed84.js></script><aside class=search-modal id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Search</h1></div><div class="col-6 col-search-close"><a class=js-search href=# aria-label=Close><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Search... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search class=form-control aria-label=Search...></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><div class="page-header header--fixed"><header><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container-xl><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=/>Mars Huang</a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar-content aria-expanded=false aria-label="Toggle navigation">
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=/>Mars Huang</a></div><div class="navbar-collapse main-menu-item collapse justify-content-start" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=/#about><span>About</span></a></li><li class=nav-item><a class=nav-link href=/#featured><span>Featured</span></a></li><li class=nav-item><a class=nav-link href=/#publications><span>Publications</span></a></li><li class=nav-item><a class=nav-link href=/#experiences><span>Experiences</span></a></li><li class=nav-item><a class=nav-link href=/#photos><span>Photography</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class="nav-item d-none d-lg-inline-flex"><a class=nav-link href=https://twitter.com/MarsScHuang data-toggle=tooltip data-placement=bottom title="Follow me on Twitter" target=_blank rel=noopener aria-label="Follow me on Twitter"><i class="fab fa-twitter" aria-hidden=true></i></a></li><li class=nav-item><a class="nav-link js-search" href=# aria-label=Search><i class="fas fa-search" aria-hidden=true></i></a></li><li class="nav-item dropdown theme-dropdown"><a href=# class=nav-link data-toggle=dropdown aria-haspopup=true aria-label="Display preferences"><i class="fas fa-moon" aria-hidden=true></i></a><div class=dropdown-menu><a href=# class="dropdown-item js-set-theme-light"><span>Light</span></a>
<a href=# class="dropdown-item js-set-theme-dark"><span>Dark</span></a>
<a href=# class="dropdown-item js-set-theme-auto"><span>Automatic</span></a></div></li></ul></div></nav></header></div><div class=page-body><div class=pub><div class="article-container pt-3"><h1>Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials</h1><div class=article-metadata><div><span>Andre Esteva</span>, <span>Jean Feng</span>, <span>Douwe van der Wal</span>, <span class=author-highlighted>Mars (Shih-Cheng) Huang</span>, <span>Jeffry P Simko</span>, <span>Sandy DeVries</span>, <span>Emmalyn Chen</span>, <span>Edward M Schaeffer</span>, <span>Todd M Morgan</span>, <span>Yilun Sun</span>, <span>Amirata Ghorbani</span>, <span>Nikhil Naik</span>, <span>Dhruv Nathawani</span>, <span>Richard Socher</span>, <span>Jeff M Michalski</span>, <span>Mack Roach III</span>, <span>Thomas M Pisansky</span>, <span>Jedidiah M Monson</span>, <span>Farah Naz</span>, <span>James Wallace</span>, <span>Michelle J Ferguson</span>, <span>Jean-Paul Bahary</span>, <span>James Zou</span>, <span>Matthew Lungren</span>, <span>Serena Yeung</span>, <span>Ashley E Ross</span>, <span>Howard M Sandler</span>, <span>Phuoc T Tran</span>, <span>Daniel E Spratt</span>, <span>Stephanie Pugh</span>, <span>Felix Y Feng</span>, <span>Osama Mohamad</span>, <span>NRG Prostate Cancer AI Consortium</span></div><span class=article-date>April, 2022</span></div><div class="btn-links mb-3"><a class="btn btn-outline-primary btn-page-header" href=https://www.nature.com/articles/s41746-022-00613-w target=_blank rel=noopener>PDF</a>
<a href=# class="btn btn-outline-primary btn-page-header js-cite-modal" data-filename=/publication/prostate_multimodal/cite.bib>Cite</a>
<a class="btn btn-outline-primary btn-page-header" href=https://doi.org/https://doi.org/10.1038/s41746-022-00613-w target=_blank rel=noopener>DOI</a></div></div><div class="article-header article-container featured-image-wrapper mt-4 mb-4" style=max-width:685px;max-height:472px><div style=position:relative><img src=/publication/prostate_multimodal/featured_hu16f6646f446ccfd4e904ae48d07608f2_85684_720x2500_fit_q75_h2_lanczos.webp width=685 height=472 alt class=featured-image></div></div><div class=article-container><h3>Abstract</h3><p class=pub-abstract>Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient’s optimal therapy is a challenge, where oncologists must select a therapy with the highest likelihood of success and the lowest likelihood of toxicity. International standards for prognostication rely on non-specific and semi-quantitative tools, commonly leading to over- and under-treatment. Tissue-based molecular biomarkers have attempted to address this, but most have limited validation in prospective randomized trials and expensive processing costs, posing substantial barriers to widespread adoption. There remains a significant need for accurate and scalable tools to support therapy personalization. Here we demonstrate prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies. We train and validate models using five phase III randomized trials conducted across hundreds of clinical centers. Histopathological data was available for 5654 of 7764 randomized patients (71%) with a median follow-up of 11.4 years. Compared to the most common risk-stratification tool—risk groups developed by the National Cancer Center Network (NCCN)—our models have superior discriminatory performance across all endpoints, ranging from 9.2% to 14.6% relative improvement in a held-out validation set. This artificial intelligence-based tool improves prognostication over standard tools and allows oncologists to computationally predict the likeliest outcomes of specific patients to determine optimal treatment. Outfitted with digital scanners and internet access, any clinic could offer such capabilities, enabling global access to therapy personalization.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Type</div><div class="col-12 col-md-9"><a href=/publication/#2>Journal article</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publication</div><div class="col-12 col-md-9">In <em>Nature Digital Medicine</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style></div><div class=share-box><ul class=share><li><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fmarshuang80.github.io%2Fpublication%2Fprostate_multimodal%2F&text=Prostate+cancer+therapy+personalization+via+multi-modal+deep+learning+on+randomized+phase+III+clinical+trials" target=_blank rel=noopener class=share-btn-twitter aria-label=twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https%3A%2F%2Fmarshuang80.github.io%2Fpublication%2Fprostate_multimodal%2F&t=Prostate+cancer+therapy+personalization+via+multi-modal+deep+learning+on+randomized+phase+III+clinical+trials" target=_blank rel=noopener class=share-btn-facebook aria-label=facebook><i class="fab fa-facebook"></i></a></li><li><a href="mailto:?subject=Prostate%20cancer%20therapy%20personalization%20via%20multi-modal%20deep%20learning%20on%20randomized%20phase%20III%20clinical%20trials&body=https%3A%2F%2Fmarshuang80.github.io%2Fpublication%2Fprostate_multimodal%2F" target=_blank rel=noopener class=share-btn-email aria-label=envelope><i class="fas fa-envelope"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fmarshuang80.github.io%2Fpublication%2Fprostate_multimodal%2F&title=Prostate+cancer+therapy+personalization+via+multi-modal+deep+learning+on+randomized+phase+III+clinical+trials" target=_blank rel=noopener class=share-btn-linkedin aria-label=linkedin-in><i class="fab fa-linkedin-in"></i></a></li><li><a href="whatsapp://send?text=Prostate+cancer+therapy+personalization+via+multi-modal+deep+learning+on+randomized+phase+III+clinical+trials%20https%3A%2F%2Fmarshuang80.github.io%2Fpublication%2Fprostate_multimodal%2F" target=_blank rel=noopener class=share-btn-whatsapp aria-label=whatsapp><i class="fab fa-whatsapp"></i></a></li><li><a href="https://service.weibo.com/share/share.php?url=https%3A%2F%2Fmarshuang80.github.io%2Fpublication%2Fprostate_multimodal%2F&title=Prostate+cancer+therapy+personalization+via+multi-modal+deep+learning+on+randomized+phase+III+clinical+trials" target=_blank rel=noopener class=share-btn-weibo aria-label=weibo><i class="fab fa-weibo"></i></a></li></ul></div><div class="media author-card content-widget-hr"><a href=https://marshuang80.github.io><img class="avatar mr-3 avatar-circle" src=/authors/admin/avatar_hu0647cedca97c4c8f561204cc83f5d37a_415564_270x270_fill_q75_lanczos_center.jpg alt="Mars (Shih-Cheng) Huang"></a><div class=media-body><h5 class=card-title><a href=https://marshuang80.github.io>Mars (Shih-Cheng) Huang</a></h5><h6 class=card-subtitle>Ph.D. Candidate @</h6><ul class=network-icon aria-hidden=true><li><a href=https://twitter.com/MarsScHuang target=_blank rel=noopener><i class="fab fa-twitter"></i></a></li><li><a href="https://scholar.google.com/citations?hl=en&user=RLMiaZUAAAAJ" target=_blank rel=noopener><i class="fas fa-graduation-cap"></i></a></li><li><a href=https://github.com/marshuang80 target=_blank rel=noopener><i class="fab fa-github"></i></a></li><li><a href=https://www.linkedin.com/in/mschuang/ target=_blank rel=noopener><i class="fab fa-linkedin"></i></a></li><li><a href=/uploads/resume.pdf><i class="ai ai-cv"></i></a></li></ul></div></div></div></div></div><div class=page-footer><div class=container><footer class=site-footer><p class="powered-by copyright-license-text">© 2023 Me. This work is licensed under <a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank>CC BY NC ND 4.0</a></p><p class="powered-by footer-license-icons"><a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank aria-label="Creative Commons"><i class="fab fa-creative-commons fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-by fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nc fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nd fa-2x" aria-hidden=true></i></a></p><p class=powered-by>Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target=_blank rel=noopener>Wowchemy</a> — the free, <a href=https://github.com/wowchemy/wowchemy-hugo-themes target=_blank rel=noopener>open source</a> website builder that empowers creators.</p></footer></div></div><script src=/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js></script>
<script id=search-hit-fuse-template type=text/x-template>
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script><script src=https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin=anonymous></script>
<script id=page-data type=application/json>{"use_headroom":true}</script><script src=/js/wowchemy-headroom.db4755770454eb63685f8de785c0a172.js type=module></script>
<script src=/en/js/wowchemy.min.e8ee06ba8371980ffde659871dd593b0.js></script><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Cite</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i> Copy</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i> Download</a><div id=modal-error></div></div></div></div></div><script src=/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js type=module></script></body></html>